Erik Schropp

Erik Schropp currently works at C&P Investors Ltd., as Chief Executive Officer from 2020, Esperante Investments S.
r.l., as Chief Executive Officer from 2020, Haydn Holding AB, as Director from 2012, PolyPeptide Group AG, as Non-Executive Director from 2021, SEVER Life Sciences BV, as Director from 2019, Draupnir Holding BV, as Director from 2008, and Ferring Foundation BV, as Director from 2008.
Mr. Schropp also formerly worked at Ferring Pharmaceuticals A, as Director-International Tax & Finance from 1999 to 2005, Altacor Ltd., as Director from 2014 to 2017, PolyPeptide Laboratories Holding BV, as Director from 2017 to 2021, PolyPeptide Laboratories Holding (PPL) AB, as Director from 2017 to 2021, FinVector Oy, as Director from 2020 to 2021, Unisource NV, as Manager-International Tax from 1996 to 1999, and Arthur Andersen Accountants, as Tax Manager from 1988 to 1996.
Mr. Schropp received his graduate degree in 1988 from Erasmus University Rotterdam.